ログイン 会員登録
icon_bulk_order一括注文 Acrobiosystems for English
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
phone
Your Position: ホーム > TYRO3

TYRO3

概要

Name:TYRO3 protein tyrosine kinase
Target Synonym:Tyrosine-Protein Kinase RSE,BYK,Tyrosine-Protein Kinase Receptor TYRO3,Tyrosine-Protein Kinase BYK,Etk-2,Rek,DTK,SKY,TIF,Brt,RSE,Tyrosine-protein kinase DTK,Tyrosine-protein kinase SKY,TYRO3,Tyrosine-protein kinase TIF,TYRO3 Protein Tyrosine Kinase
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:1
Lastest Research Phase:Approved

製品リスト製品比較と製品注文

製品仕様別:
製品カテゴリー別:
種類別:
タグ別:
コンジュゲート:
製造番号 種類 製品説明 構造 純度 特徴
TY3-H5251 Human Human TYRO3 / Dtk Protein, Fc Tag
TY3-H5251-structure
TY3-H5251-sds
ACRO Quality

生物活性データの一部

TY3-H5251-ELISA
 TYRO3 ELISA

Immobilized Human GAS6 Protein, His Tag (Cat. No. GA6-H5246) at 10 μg/mL (100 μL/well) can bind Human TYRO3, Fc Tag (Cat. No. TY3-H5251) with a linear range of 2.5-20 ng/mL (QC tested).

Synonym Name

TYRO3,BYK,DTK,RSE,SKY,TIF

Background

Tyrosine-protein kinase receptor TYRO3 is also known as Tyrosine-protein kinase BYK, DTK, RSE, SKY, TIF, which belongs to the protein kinase superfamily, Tyr protein kinase family and AXL/UFO subfamily. TYRO3 regulates many physiological processes including cell survival, migration and differentiation. TYRO3 activates the AKT survival pathway, including nuclear translocation of NF-kappa-B and up-regulation of transcription of NF-kappa-B-regulated genes. TYRO3 interacts (via N-terminus) with extracellular ligands TULP1 and GAS6 By similarity and also interacts with PIK3R1, this interaction increases PI3-kinase activity.

Clinical and Translational Updates

公開薬物情報

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Cabozantinib S-malate XL-184; BMS-907351 Approved Exelixis Inc Cometriq, Cabometyx United States Carcinoma, Neuroendocrine; Thyroid Neoplasms Exelixis Inc 2012-11-29 Carcinoma, Adenosquamous; Uterine Neoplasms; Thyroid Neoplasms; Hepatic Insufficiency; Gliosarcoma; Bile Duct Neoplasms; Peritoneal Neoplasms; Astrocytoma; Colorectal Neoplasms; Brain Neoplasms; Endometrial Neoplasms; Osteosarcoma; Urethral Neoplasms; Adenocarcinoma, Clear Cell; Neuroblastoma; Neurofibroma, Plexiform; Cholangiocarcinoma; Medullary thyroid cancer (MTC); Sarcoma, Ewing; Breast Neoplasms; Carcinoma, Endometrioid; Neoplasms, Germ Cell and Embryonal; Meningioma; Melanoma; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Thyroid Cancer, Papillary; Neoplasm Metastasis; Paraganglioma; Carcinoma, Hepatocellular; Sarcoma, Clear Cell; Carcinoma, Neuroendocrine; Fallopian Tube Neoplasms; Brain metastases; Lymphoma; Leukemia, Myeloid, Acute; Sarcoma, Alveolar Soft Part; Glioma; Carcinoma, Squamous Cell; Pain; Adrenal Cortex Neoplasms; Pancreatic neuroendocrine tumors (pNET); Glioblastoma; Kidney Diseases; Hepatoblastoma; Pheochromocytoma; Carcinoma, Renal Cell; Rejection of liver transplantation; Carcinoid Details

臨床試験情報

Name Research Code Research Phase Company Indications Clinical Trials
Insulin transdermal (Phosphagenics) TPM-02 Phase 2 Clinical Phosphagenics Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Primary Ovarian Insufficiency Details

This web search service is supported by Google Inc.

totopphone